Amarin's Vascepa Sales Jump 34% in Q2 Despite COVID-19 Headwinds
It's been a downright miserable year for Amarin (NASDAQ: AMRN) so far. The stock imploded earlier this year after a judge invalidated key patents for hypertriglyceridemia drug Vascepa. And Amarin's shares are still down nearly 70% year to date.
Investors hoped for at least a little bit of good news when Amarin announced its second-quarter results before the market opened on Tuesday. That's what they got. Here are the highlights from Amarin's Q2 update.
Image source: Getty Images.
Source Fool.com